Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

0%

0 of 7 completed trials have results

Key Signals

Enrollment Performance

Analytics

Phase 1
6(85.7%)
Phase 2
1(14.3%)
7Total
Phase 1(6)
Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials
NCT01928147Phase 1Completed

A Phase 1a/1b Study of PPI-383 in Healthy Adults and Hepatitis C Patients

Role: lead

NCT01859962Phase 2Completed

Study of PPI-668, BI 207127 and Faldaprevir, With and Without Ribavirin, in the Treatment of Chronic Hepatitis C

Role: lead

NCT02258321Phase 1Completed

Phase 1 Study of Relative Bioavailability of PPI-668 New Tablet Versus Capsule Formulations

Role: lead

NCT01979484Phase 1Completed

Phase 1 Study of Relative Bioavailability of PPI-668 Tablet and Capsule Formulations

Role: lead

NCT01786382Phase 1Completed

A Drug Interaction Study of the Effects of PPI-668 on the Pharmacokinetics of Midazolam and Omeprazole

Role: lead

NCT01448200Phase 1Completed

A Phase 1 Study of PPI-668 in Healthy Volunteers and Patients With Hepatitis C Virus (HCV) Genotype 1

Role: lead

NCT01247194Phase 1Completed

A Phase 1b Study of PPI-461 in Patients With HCV Genotype 1

Role: lead

All 7 trials loaded